Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 31 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMACON from Gent, company number BE0457066176, closed financial year 2025 with a result of € -33,237 after tax. For that financial year PHARMACON recorded a gross margin of € -11,046 and equity of € 275,949. Compared with financial year 2024, the result moved from € -30,092 to € -33,237. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.
€ 275,949
▼ 11% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -33,237
▼ 10 % more loss than in 2024
Profit after tax over the fiscal year.
€ 6,969
▼ 70% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 255,498.
People and assets in 2025
€ 969
▼ 50% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 96,764
▼ 10% vs 2024
€ 12,457 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.
€ 3,216
▼ 34% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 24,817 | € -25,327 | € -10,082 | € -11,046 | ▼ € 964 |
| Profit after taxes | € 7,556 | € -47,079 | € -30,092 | € -33,237 | ▼ € 3,145 |
| Equity | € 386,357 | € 339,278 | € 309,186 | € 275,949 | ▼ 11% |
| Total debts | € 172,777 | € 172,450 | € 199,984 | € 113,488 | ▼ 43% |
| Cash | € 56,023 | € 18,813 | € 22,944 | € 6,969 | ▼ 70% |
| Land & buildings | € 451,944 | € 451,944 | € 441,312 | € 430,681 | ▼ 2% |
| Retained profit | € 367,765 | € 320,686 | € 288,735 | € 255,498 | ▼ 12% |
| Bank debt | € 126,202 | € 116,471 | € 107,520 | € 96,764 | ▼ 10% |
| Balance sheet total | € 616,443 | € 566,991 | € 562,386 | € 440,606 | ▼ 22% |
Key figures of PHARMACON, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMACON?
What happened at PHARMACON in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 33,237. Source: NBB ↗
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 7,556 profit in 2022 to € 33,237 loss in 2025.
Paid € 22,596 in corporate taxes since 2022.
Best year ever: 2022, with € 7,556 profit.
Management
Behind PHARMACON is Conrad DEVOS.
Directors
According to the 2025 annual accounts
Conrad DEVOS
Manager
Establishments
Establishment units
Physical locations of this company
Filaturestraat 20 box 301
9000 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0457.066.176
- VAT number
- BE 0457.066.176
- Registered office
- Filaturestraat 20 bus 301, 9000 Gent
- Names & denominations
- PHARMACON
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 January 1996
- Peppol
- Active · Active since 18 Jun 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering